Loading…
Loading…
CSF (VictoryShares US Discovery Enhanced Volatility Wtd ETF) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
See exactly how CSF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CSF and 80,000+ other tickers.
The VictoryShares US Discovery Enhanced Volatility Wtd ETF endeavors to match the investment returns of the Nasdaq VictoryUS Small Cap 500 Long/Cash Volatility Weighted Index (known as the "Long/Cash Index"), excluding any charges for fees and expenses. Its distinct Volatility Weighting Methodology incorporates both fundamental criteria and volatility as factors in an attempt to surpass the performance of conventional market capitalization-weighted indexing strategies. The underlying Long/Cash Index actively manages market risk by strategically decreasing its equity market involvement during…
Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF circulating tumor cells alongside tumor-derived DNA and broaden the leptomeningeal treatment algorithm from “CSF cytology” to “CSF analysis” Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF circulating tumor cells alongside tumor-derived DNA and broaden the leptomeningeal treatment algorithm from “CSF cytology” to “CSF analysis”
[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranerse
Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from the College of American Pathologists, a widely recognized standard in laboratory quality, sending shares of the Nasdaq-listed company up 8.7% to $5.89 Thursday. CNSide Diagnostics' Houston-based clinical laboratory underwent a rigorous on-site inspection evaluating clinical protocols, documentation, quality control procedures, personnel qualifications, equipment, facilities, and overall laboratory management.
New dedicated billing code facilitates payer reimbursement, supports clinician adoptions, and enables national utilization tracking New dedicated billing code facilitates payer reimbursement, supports clinician adoptions, and enables national utilization tracking
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today announces a new payer coverage agreement with Highmark, effective April 1, 2026, providing reimbursement for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay for patients with metastatic central nervous system cancers. Highmark joins a growing list of national and regional payers, including United Healthcare and Humana, that provide coverage for CNSide.